BIOMAT Database Logo BIOMAT Database Logo

Experiences with thymosin in primary immunodeficiency disease. 1978

A Astaldi, and G C Astaldi, and P Wijermans, and F Dagna-Bricarelli, and L Kater, and J W Stoop, and J M Vossen

Thymosin has no effect in vitro on cyclic AMP levels in thymocytes. However, when thymosin was injected into patients lacking "serum factor" (SF) activity, it induced the appearance of SF or SF-like activity and the disappearance of target cells for SF among the peripheral blood lymphocytes of the treated patients. On the other hand, when thymosin was injected into one patient with normal SF activity, it induced a marked decrease of SF activity and the appearance of target cells for SF among the peripheral blood lymphocytes of this particular patient.

UI MeSH Term Description Entries
D007153 Immunologic Deficiency Syndromes Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral. Antibody Deficiency Syndrome,Deficiency Syndrome, Immunologic,Deficiency Syndromes, Antibody,Deficiency Syndromes, Immunologic,Immunologic Deficiency Syndrome,Immunological Deficiency Syndromes,Antibody Deficiency Syndromes,Deficiency Syndrome, Antibody,Deficiency Syndrome, Immunological,Deficiency Syndromes, Immunological,Immunological Deficiency Syndrome,Syndrome, Antibody Deficiency,Syndrome, Immunologic Deficiency,Syndrome, Immunological Deficiency,Syndromes, Antibody Deficiency,Syndromes, Immunologic Deficiency,Syndromes, Immunological Deficiency
D007223 Infant A child between 1 and 23 months of age. Infants
D007231 Infant, Newborn An infant during the first 28 days after birth. Neonate,Newborns,Infants, Newborn,Neonates,Newborn,Newborn Infant,Newborn Infants
D008297 Male Males
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000242 Cyclic AMP An adenine nucleotide containing one phosphate group which is esterified to both the 3'- and 5'-positions of the sugar moiety. It is a second messenger and a key intracellular regulator, functioning as a mediator of activity for a number of hormones, including epinephrine, glucagon, and ACTH. Adenosine Cyclic 3',5'-Monophosphate,Adenosine Cyclic 3,5 Monophosphate,Adenosine Cyclic Monophosphate,Adenosine Cyclic-3',5'-Monophosphate,Cyclic AMP, (R)-Isomer,Cyclic AMP, Disodium Salt,Cyclic AMP, Monoammonium Salt,Cyclic AMP, Monopotassium Salt,Cyclic AMP, Monosodium Salt,Cyclic AMP, Sodium Salt,3',5'-Monophosphate, Adenosine Cyclic,AMP, Cyclic,Adenosine Cyclic 3',5' Monophosphate,Cyclic 3',5'-Monophosphate, Adenosine,Cyclic Monophosphate, Adenosine,Cyclic-3',5'-Monophosphate, Adenosine,Monophosphate, Adenosine Cyclic
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

A Astaldi, and G C Astaldi, and P Wijermans, and F Dagna-Bricarelli, and L Kater, and J W Stoop, and J M Vossen
Thymosin treatment of children with primary immunodeficiency disease.
March 1978, Transplantation proceedings,
A Astaldi, and G C Astaldi, and P Wijermans, and F Dagna-Bricarelli, and L Kater, and J W Stoop, and J M Vossen
Thymosin activity in patients with cellular immunodeficiency.
January 1975, The New England journal of medicine,
A Astaldi, and G C Astaldi, and P Wijermans, and F Dagna-Bricarelli, and L Kater, and J W Stoop, and J M Vossen
In vitro and in vivo enhancement of mixed lymphocyte culture reactivity by thymosin in patients with primary immunodeficiency disease.
January 1979, Annals of the New York Academy of Sciences,
A Astaldi, and G C Astaldi, and P Wijermans, and F Dagna-Bricarelli, and L Kater, and J W Stoop, and J M Vossen
Immunologic reconstitution of patients with primary immunodeficiency diseases and cancer after treatment with thymosin.
March 1977, Transplantation proceedings,
A Astaldi, and G C Astaldi, and P Wijermans, and F Dagna-Bricarelli, and L Kater, and J W Stoop, and J M Vossen
Use of thymosin in the treatment of primary immunodeficiency diseases and cancer.
May 1976, The Medical clinics of North America,
A Astaldi, and G C Astaldi, and P Wijermans, and F Dagna-Bricarelli, and L Kater, and J W Stoop, and J M Vossen
Thymosin for immunodeficiency diseases and cancer.
February 1978, Comprehensive therapy,
A Astaldi, and G C Astaldi, and P Wijermans, and F Dagna-Bricarelli, and L Kater, and J W Stoop, and J M Vossen
Multicentric castleman disease in a child with primary immunodeficiency.
December 2010, Pediatric blood & cancer,
A Astaldi, and G C Astaldi, and P Wijermans, and F Dagna-Bricarelli, and L Kater, and J W Stoop, and J M Vossen
Ischaemic heart disease in primary immunodeficiency.
November 1998, Lancet (London, England),
A Astaldi, and G C Astaldi, and P Wijermans, and F Dagna-Bricarelli, and L Kater, and J W Stoop, and J M Vossen
Progressive encephalopathy in primary immunodeficiency disease.
January 2002, Clinical immunology (Orlando, Fla.),
A Astaldi, and G C Astaldi, and P Wijermans, and F Dagna-Bricarelli, and L Kater, and J W Stoop, and J M Vossen
Primary immunodeficiency disease presenting in midlife.
December 1996, JAMA,
Copied contents to your clipboard!